SYNTHESIS AND MOLECULAR DOCKING OF N,N'-[SUCCINYLBIS(OXY)]DIBENZAMIDES AS INHIBITORS OF CATHEPSIN S AND CATHEPSIN K

Authors: Yulia A. Trukhanova, Boris Y. Lalaev, Anna A. Vakhnina




St. Petersburg State University of Chemistry and Pharmacy, St. Petersburg, 197376 Russia Corresponding author: Yulia. A. Trukhanova E-mail: truhanova.yuliya@pharminnotech.com



Introduction


Suberoylanilide of hydroxamic acid, available under the trade name Vorinostat, has been used as a drug in the treatment of T-cell lymphoma



Obtaining compounds of a similar structure, namely, containing in their structure a hydroxamic component, an aromatic ring and a saturated hydrocarbon radical can be a step towards the creation of new drugs.


hydroxamic component

We have studied the reaction of interaction of benzhydroxamic acids with succinyl chloride. It was found that during boiling in acetonitrile N/N'-[succinylbis(oxy)]dibenzamides 6a,b are formed




component


Commercially available benzoic acids **1a,b** were used as starting reagents for the synthesis of **6a,b**. The synthesis was carried out in three stages



Typical 1H NMR spectrum for compounds **6a,b** by the example of 1H NMR spectrum for **6a**. The spectrum was recorded in DMSO-d6 (400 MHz) relatively tetramethylsilane as internal standard




Biological activity by PASS-online for compounds 6a,b



Pa	Pi	Activity name
0,929	0,001	Growth hormone agonist
0,529	0,016	GABA aminotransferase inhibitor
0,544	0,039	Antiarthritic
0,550	0,099	Fibrinolytic
0,475	0,070	Cytoprotectant
0,436	0,037	Cathepsin T inhibitor

Ра
0,882
0,579
0,465
0,444
0,404
0,380
0,329
0,187

 O_2N_{\sim}





6b

Pi	Activity name
0,001	Growth hormone agonist
0,020	Radiosensitizer
0,068	Antiviral (Picornavirus)
0,057	Antihypoxic
0,051	Chemosensitizer
0,057	GABA aminotransferase inhibitor
0,067	Antiviral (Adenovirus)
0,143	Cathepsin T inhibitor

In order to search for the most active inhibitors of Cathepsin proteases, we studied the molecular docking of the obtained dibenzamides **6a,b** and their analogs. The study was carried out in the online program Mcule, where Cathepsins S (2hxz) and K (1tu6) were selected as a receptor.

Analysis in the Mcule program using the example of N,N'-(succinylbis(oxy))bis(3-methylbenzamide).






Cathepsin K


Cathepsin S

Results and discussion Imcule

It was found that methyl -, fluoro - and chlorinesubstituted dibenzamides have a higher affinity for binding to Cathepsin. It should be noted that all compounds, with the exception of 6g, have a higher affinity for Cathepsin K than for Cathepsin S.




In order to carry out further synthesis of the most promising molecules, a semi-empirical calculation of charges on oxygen and nitrogen atoms in the corresponding initial benzhydroxamic acids was performed. The calculation was performed using the HyperChem software package using the AM1 method





Based on the above, it is more expedient to obtain methyl-substituted dibenzamides for further *in vivo* biological activity research



arge or nitroge ntom
),187
),191
),317
),315
),316

Conclusion

- As a result of the reaction of acylation of benzhydroxamic acids with succinyl chloride in acetonitrile medium, N,N'-[succinylbis(oxy)]dibenzamides were obtained.
- Their structure was proved by 1H and 13C NMR.
- Using the PASS program, information on the biological activity of new molecules was obtained, in particular, the property of inhibition of Cathepsin proteases was found.
- Using the Mcule program, the values of the affinity of the synthesized dibenzamides and their analogs with Cathepsins S and K were obtained. It was revealed that fluoro-, methyl-, and chlorine-substituted dibenzamides have the highest affinity for Cathepsins S and K.
- Using the HyperChem program, the possibility of obtaining the dibenzamides of interest was analyzed and a conclusion was made about the feasibility of obtaining methyl-substituted dibenzamides in order to further study the biological activity in vivo.

Thank you for your attention!



Corresponding author: Yulia. A. Trukhanova E-mail: truhanova.yuliya@pharminnotech.com